Literature DB >> 16809043

Antitumor agents 251: synthesis, cytotoxic evaluation, and structure-activity relationship studies of phenanthrene-based tylophorine derivatives (PBTs) as a new class of antitumor agents.

Linyi Wei1, Arnold Brossi, Ross Kendall, Kenneth F Bastow, Susan L Morris-Natschke, Qian Shi, Kuo-Hsiung Lee.   

Abstract

Polar phenanthrene-based tylophorine derivatives (PBTs) were designed, synthesized and evaluated as potential antitumor agents. These compounds contain a core phenanthrene structure and can be synthesized efficiently in excellent yield. The newly synthesized PBTs were evaluated for cytotoxic activity against the A549 human cancer cell line. Among them, N-(2,3-methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-2-piperidinemethanol (34) and N-(2,3-methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-5-aminopentanol (28) showed the highest potency with IC50 values of 0.16 and 0.27 microM, respectively, which are comparable to those of currently used antitumor drugs. A structure-activity relationship (SAR) study was also explored to facilitate the further development of this new compound class.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809043     DOI: 10.1016/j.bmc.2006.06.009

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Total synthesis of (S)-(+)-tylophorine via enantioselective intramolecular alkene carboamination.

Authors:  Wei Zeng; Sherry R Chemler
Journal:  J Org Chem       Date:  2008-06-28       Impact factor: 4.354

Review 2.  Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.

Authors:  Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

3.  Total Syntheses and Cytotoxicity of (R)- and (S)-Boehmeriasin A.

Authors:  Matthew W Leighty; Gunda I Georg
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

4.  Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy.

Authors:  Sherry R Chemler
Journal:  Curr Bioact Compd       Date:  2009-03-01

5.  Lead Optimization: Synthesis and Biological Evaluation of PBT-1 Derivatives as Novel Antitumor Agents.

Authors:  Lan Xie; Masuo Goto; Xiaoyan Chen; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  ACS Med Chem Lett       Date:  2021-11-17       Impact factor: 4.345

6.  Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.

Authors:  Jau-Chen Lin; Shuenn-Chen Yang; Tse-Ming Hong; Sung-Liang Yu; Qian Shi; Linyi Wei; Hsuan-Yu Chen; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

7.  Structural analogs of tylophora alkaloids may not be functional analogs.

Authors:  Wenli Gao; Annie Pei-Chun Chen; Chung-Hang Leung; Elizabeth A Gullen; Alois Fürstner; Qian Shi; Linyi Wei; Kuo-Hsiung Lee; Yung-Chi Cheng
Journal:  Bioorg Med Chem Lett       Date:  2007-11-21       Impact factor: 2.823

8.  Antitumor agents 268. Design, synthesis, and mechanistic studies of new 9-substituted phenanthrene-based tylophorine analogues as potent cytotoxic agents.

Authors:  Xiaoming Yang; Qian Shi; Yi-Nan Liu; Guiyu Zhao; Kenneth F Bastow; Jau-Chen Lin; Shuenn-Chen Yang; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

9.  Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents.

Authors:  Shuxing Zhang; Linyi Wei; Ken Bastow; Weifan Zheng; Arnold Brossi; Kuo-Hsiung Lee; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2007-03-06       Impact factor: 3.686

10.  Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index.

Authors:  Ameya R Kirtane; Henry L Wong; Bharath Raja Guru; Lev G Lis; Gunda I Georg; Vadim J Gurvich; Jayanth Panyam
Journal:  Mol Pharm       Date:  2015-07-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.